Prospective comparison of subcutaneous vs intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and

被引：0
|
作者：
Moreau, P.
Coiteux, V.
Hulin, C.
Facon, T.
van de Velde, H.
Acharya, M.
Harousseau, J. L.
机构：
[1] Univ Hosp Nantes, Dept Hematol, Nantes, France
[2] Johnson & Johnson Pharmaceut R&D, Beerse, Belgium
[3] Johnson & Johnson Pharmaceut R&D, Raritan, NJ USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [41] Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys
    Leeds, JM
    Henry, SP
    Geary, R
    Burckin, T
    Levin, AA
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2000, 10 (06): : 435 - 441
  • [42] Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses
    Chiavaccini, L.
    Claude, A. K.
    Lee, J. H.
    Ross, M. K.
    Meyer, R. E.
    Langston, V. C.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2015, 38 (04) : 365 - 374
  • [43] An evaluation of efficiency, safety, tolerability, patient satisfaction, and preference of subcutaneous (SQ) versus intravenous (IV) bortezomib (BTZ) administration in patients with multiple myeloma (MM).
    Barbee, Meagan Spencer
    Wilson, Nicole Maire
    Harvey, R. Donald
    McKibbin, Trevor
    Lonial, Sagar
    Kaufman, Jonathan L.
    Shah, Katherine Sanvidge
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] A PHARMACOKINETICS CLINICAL STUDY OF BORTEZOMIB SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS INJECTION COMBINED WITH CHEMOTHERAPY IN CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA-INTERIM RESULTS
    Fu, C.
    Wu, D.
    Zhu, X.
    Jin, S.
    Yan, L.
    Yan, S.
    Wang, P.
    Ge, Y.
    Chang, M.
    HAEMATOLOGICA, 2016, 101 : 794 - 794
  • [45] Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novopatients with multiple myeloma
    刘辉
    China Medical Abstracts (Internal Medicine), 2013, 30 (04) : 229 - 230
  • [46] Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
    Arnulf, Bertrand
    Pylypenko, Halyna
    Groslcki, Sebastian
    Karamanesht, Ievgenii
    Leleu, Xavier
    van de Velde, Helgi
    Feng, Huaibao
    Cakana, Andrew
    Deraedt, William
    Moreau, Philippe
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12): : 1925 - 1928
  • [47] COMPARATIVE EFFICIENCY OF SUBCUTANEOUS AND INTRAVENOUS BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA: SUMMING UP THE RECORDS OF MUNICIPAL HEMATOLOGICAL CENTER, NOVOSIBIRSK
    Pospelova, T., I
    Skvortsova, N., V
    Nechunaeva, I. N.
    Tairova, S. A.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2015, 60 (02): : 15 - 20
  • [48] RETROSPECTIVE STUDY OF THE EFFICACY, ECONOMY AND SAFETY OF TREATMENT WITH SUBCUTANEOUS INJECTION OF BORTEZOMIB IN DE NOVO PATIENTS WITH MULTIPLE MYELOMA
    Yan, S.
    Wang, P.
    Xu, Y.
    Zheng, H.
    Ma, L.
    Jin, S.
    Fu, C.
    Wu, D.
    HAEMATOLOGICA, 2016, 101 : 801 - 802
  • [49] EFFICACY, SAFETY AND TOLERANCE OF BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
    Ballina, B.
    Fuertes, M.
    Cerda, S.
    Martinez Robles, V
    Gonzalez, P.
    Rondon, F.
    Yacoubi, S.
    Rodriguez, J. A.
    Escalante, F.
    HAEMATOLOGICA, 2017, 102 : 94 - 95
  • [50] Tolerance and efficacy of bortezomib in patients with multiple myeloma of poor prognosis
    Leleu, Xavier
    HEMATOLOGIE, 2007, 13 (03): : 136 - 136
12345